In pancreatic cancer, there is an imbalance between the canonical Smad transduction which is debilitated due to Smad4 mutations and the noncanonical MAPK pathway which, in addition to the nonaffected transduction from TGFβ receptors, receives the input from the activated K-ras [99]. Here, KRAS is linked to pancreatic neoplasm.